We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Interleukin-10 Attenuates the Release of Proinflammatory Cytokines but Depresses Splenocyte Functions in Murine Endotoxemia

Wolfgang Ertel, MD; Marius Keel, MD; Ursula Steckholzer; Udo Ungethüm; Otmar Trentz, MD
Arch Surg. 1996;131(1):51-56. doi:10.1001/archsurg.1996.01430130053009.
Text Size: A A A
Published online


Objective:  To determine whether interleukin (IL)-10, besides its potent anti-inflammatory properties, causes depression of splenocyte functions in a murine model of gram-negative endotoxemia.

Design:  Mice (strain C3H/HeN) were injected intravenously with 1 mg of Escherichia coli lipopolysaccharide at 15 minutes after intravenous injection of either 200 U of recombinant murine IL-10 or saline solution. Serum levels of tumor necrosis factor α, IL-6, and IL-1α were determined at 90 minutes and 12 hours after lipopolysaccharide challenge. In addition, splenocyte proliferation and lymphokine release (IL-2, IL-6, and interferon gamma) were measured.

Results:  Pretreatment with IL-10 markedly reduced (P<.05) serum levels of tumor necrosis factor α (−79%), IL-6 (−94%), and IL-1α (−69%), but it significantly inhibited splenocyte proliferation (−32%) and IL-2 (−40%), IL-6 (−49%), and interferon gamma (−54%) release of splenocytes.

Conclusions:  Interleukin-10 prevents E coli lipopolysaccharide—induced cytokinemia but dampens antigen-driven cellular immune responses. Although IL-10 protects against the detrimental effects of proinflammatory cytokines by deactivation of macrophages, its immunosuppressive effect may augment susceptibility to repeated or continuous invasion of microorganisms, as it is observed during clinical sepsis.(Arch Surg. 1996;131:51-56)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.